Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 20Recurrence 19Leukemia, Myeloid, Acute 19Neoplasm Metastasis 17Colorectal Neoplasms 16Lymphoma, Non-Hodgkin 15Melanoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia 13Ovarian Neoplasms 12Lymphoma, Follicular 12Carcinoma, Renal Cell 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 10Lung Neoplasms 10Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Carcinoma, Hepatocellular 9Adenocarcinoma 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8

Interventions

zanubrutinib 1venetoclax 1pirtobrutinib 1ibrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × Waldenstrom Macroglobulinemia × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT03053440 2024-10-26

ASPEN

BeiGene

Phase 3 Completed
201 enrolled 19 charts 1 FDA
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡